Organon & Co. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Organon & Co. (OGN) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$260.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2024-02-26
- Organon & Co. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-12-31 was -$61.00M.
- Organon & Co. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-09-30 was -$213.00M.
- Organon & Co. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-06-30 was -$83.00M.
- Organon & Co. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-03-31 was -$63.00M.
- Organon & Co. net cash provided by (used in) investing activities, continuing operations for fiscal 2023 was -$260.00M.
- Organon & Co. net cash provided by (used in) investing activities, continuing operations for fiscal 2022 was -$420.00M.
- Organon & Co. net cash provided by (used in) investing activities, continuing operations for fiscal 2021 was -$481.00M.
- Organon & Co. net cash provided by (used in) investing activities, continuing operations for fiscal 2020 was -$250.00M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$260.00M 10-K · filed 2024-02-26 | |||
| 2022-12-31 | -$61.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$274.00M derived: sum of 2 quarters · filed 2024-02-26 | -$357.00M derived: sum of 3 quarters · filed 2024-02-26 | -$420.00M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$213.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$296.00M derived: sum of 2 quarters · filed 2022-11-04 | -$359.00M 10-Q · filed 2022-11-04 | -$492.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$83.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$146.00M 10-Q · filed 2022-08-05 | -$279.00M derived: sum of 3 quarters · filed 2024-02-26 | -$340.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$63.00M 10-Q · filed 2022-05-06 | -$196.00M derived: sum of 2 quarters · filed 2024-02-26 | -$257.00M derived: sum of 3 quarters · filed 2024-02-26 | -$506.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$133.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$194.00M derived: sum of 2 quarters · filed 2024-02-26 | -$443.00M derived: sum of 3 quarters · filed 2024-02-26 | -$481.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$61.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$310.00M derived: sum of 2 quarters · filed 2022-11-04 | -$348.00M 10-Q · filed 2022-11-04 | -$467.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$249.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$287.00M 10-Q · filed 2022-08-05 | -$406.00M derived: sum of 3 quarters · filed 2023-02-27 | -$451.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$38.00M 10-Q · filed 2022-05-06 | -$157.00M derived: sum of 2 quarters · filed 2023-02-27 | -$202.00M derived: sum of 3 quarters · filed 2023-02-27 | -$249.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$119.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$164.00M derived: sum of 2 quarters · filed 2023-02-27 | -$211.00M derived: sum of 3 quarters · filed 2023-02-27 | -$250.00M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$45.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$92.00M derived: sum of 2 quarters · filed 2021-11-12 | -$131.00M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$47.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$86.00M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$39.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | -$88.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |